Please login to the form below

Not currently logged in
Email:
Password:

Fabry disease

This page shows the latest Fabry disease news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Amicus’s Galafold gains FDA approval, set to rival Fabrayzme. Amicus Therapeutics has received FDA approval for Galafold, the first oral therapy for the rare Fabry disease. ... That accounts for about 35-50% of the 10, 000 diagnosed Fabry patients

Latest news

  • Freeline raises £88m to accelerate haemophilia gene therapy Freeline raises £88m to accelerate haemophilia gene therapy

    and take another for Fabry disease into the clinic. ... This adds to Freeline and its focus on chronic systemic disease, Nightstar ( specialising in inherited retinal diseases), and Gyroscope, which specialises in retinal inflammation.

  • Amicus Therapeutics launches Fabry treatment Galafold in Italy Amicus Therapeutics launches Fabry treatment Galafold in Italy

    US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after winning reimbursement coverage. ... Galafold is the first orally administered alternative to the current crop of injectable enzyme

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    The National Institute of Health and Care Excellence has given its blessing to Amicus' oral therapy for Fabry disease, a rare genetic disorder. ... Fabry disease affects an estimated 855 people in England, of whom around 140 would be eligible for

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease, an incurable inherited genetic disorder. ... greater enzyme activity after evidence of renal,

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    Fabry disease affects an estimated 855 people in England, of whom around 140 would be eligible for treatment with Galafold. ... An incurable inherited genetic disorder, Fabry disease is caused by a faulty enzyme responsible for breaking down fatty

More from news
Approximately 4 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    380 which will be used to treat cachexia, a wasting disease seen in cancer patients. ... Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Firstly, GSK decided to return rights to the experimental Fabry disease drug migalastat, noting that support would continue through GSK's equity investment of $3m. ... The deal gives Amicus access to Callidus' late-stage enzyme replacement therapy for

  • Payer focus in the personalised world of oncology and orphan diseases Payer focus in the personalised world of oncology and orphan diseases

    Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding. ... The Netherlands recently tried to withdraw public funding for late onset Fabry Disease

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Sobi names Holly May VP of sales and marketing, US Sobi names Holly May VP of sales and marketing, US

    Rare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US. ... May has had more than 20 years’experience in biopharmaceutical sales and marketing, with her most recent role serving as head of US

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Focus on Rare Diseases

    Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. ... Lucid’ s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics